## 1 A Reagent and Virus Benchmarking Panel for a Uniform Analytical Performance

## 2 Assessment of N Antigen–Based Diagnostic Tests for COVID-19

- 3 Allison Golden\*, Jason L. Cantera, Lorraine Lillis, Thanh T. Phan, Hannah Slater, Edwin J.
- 4 Webb, Roger B. Peck, Gonzalo J. Domingo, David S. Boyle
- 5
- 6 All authors: PATH; 2201 Westlake Avenue, Suite 200; Seattle, Washington 98121, USA
- 7 \*Corresponding author

## 9 ABSTRACT

Rapid diagnostic tests (RDTs) that detect antigen indicative of SARS-CoV-2 infection can help 10 11 in making quick health care decisions and regularly monitoring groups at risk of infection. With 12 many RDT products entering the market, it is important to rapidly evaluate their relative 13 performance. Comparison of clinical evaluation study results is challenged by protocol design variations and study populations. Laboratory assays were developed to quantify nucleocapsid (N) 14 15 and spike (S) SARS-CoV-2 antigens. Quantification of the two antigens in nasal eluates confirmed higher abundance of N than S antigen. The median concentration of N antigen was 10 16 times greater than S per genome equivalent. The N antigen assay was used in combination with 17 quantitative RT-PCR to qualify a panel composed of recombinant antigens, inactivated virus, and 18 19 clinical specimen pools. This benchmarking panel was applied to evaluate the analytical performance of the SD Biosensor STANDARD Q COVID-19 Ag test, Abbott Panbio COVID-19 20 Ag Rapid Test, Abbott BinaxNOW COVID-19 Ag test, and the LumiraDx SARS-CoV-2 Ag 21 22 Test. The four tests displayed different sensitivities toward the different panel members, but all 23 performed best with the clinical specimen pool. The concentration for a 90% probability of 24 detection across the four tests ranged from 21 pg/mL to 102 pg/mL of N antigen in the extracted 25 sample. Benchmarking panels provide a quick way to verify the baseline performance of a 26 diagnostic and enable direct comparison between diagnostic tests.

27

## 28 KEY WORDS

- 29 SARS-CoV-2, rapid antigen diagnostic test, rapid diagnostic test, COVID-19, screening,
- 30 nucleocapsid antigen, spike antigen, genome equivalent, PCR

## 31 ABBREVIATIONS

- 32 BEI, BEI Resources; BSA, bovine serum albumin; CDC, US Centers for Disease Control and
- Prevention; COVID-19, coronavirus disease 2019; Ct, cycle threshold; *E. coli, Escherichia coli*;
- EUA, emergency use authorization; EUL, emergency use license; GE, genome equivalent; LOD,
- limit of detection; LLOQ, lower limit of quantification; MSD, Meso Scale Discovery; N,
- 36 nucleocapsid; NIAID, US National Institute of Allergy and Infectious Diseases; NIH, US
- 37 National Institutes of Health; PBS, phosphate-buffered saline; qRT-PCR, quantitative reverse
- transcription polymerase chain reaction; RDT, rapid diagnostic test; RT-PCR, reverse
- transcription polymerase chain reaction; S, spike; SARS-CoV-2, severe acute respiratory
- 40 syndrome coronavirus 2; TCID<sub>50</sub>, 50% tissue culture infective dose; ULOQ, upper limit of
- 41 quantification.

## 42 INTRODUCTION

Diagnostic tools are essential for surveillance and control of the COVID-19 pandemic.<sup>1</sup> While 43 44 reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal or nasal swab 45 is the gold standard for confirmation of infection with SARS-CoV-2, the complexity of such tests requires sophisticated laboratory systems, and imposes logistical challenges for its effective 46 47 use in scenarios requiring either a fast time-to-result or where laboratory systems are not robust. 48 Rapid diagnostic tests (RDTs) designed to detect viral antigens, primarily the nucleocapsid protein (N) antigen, hold promise for testing in settings where RT-PCR cannot be implemented, 49 and as both time and cost-saving measures for frequent testing and entry points.<sup>1-3</sup> 50 51 The earliest-to-market RDTs were tested in clinical studies to assess their performance and 52 utility. The results of these clinical studies are informative in terms of clinical performance 53 within the context of the studies conducted, but they also highlight the variability in clinical performance as driven by the study design, target population, and other study-specific factors. <sup>4–6</sup> 54 55 There is need for a performance assessment of these tests that is less study specific and can be 56 performed in multiple laboratories, the results of which would enable more direct comparison of performance across different RDTs.<sup>7</sup> If the results of this assessment can be linked to clinical 57 data, they may also be indicative of clinical performance. Currently, assessments of analytical 58 59 performance have been expressed primarily through comparison to SARS-CoV-2 viral RNA in 60 terms of cycle thresholds (Ct) or to cultured virus infective units, with increasing correlation to viral copy number quantification to aid in standardization of results.<sup>7-13</sup> Complementary to these 61 62 efforts, this article presents a quantitative open-platform assay for the N and spike (S) antigens, a 63 comparison of genome equivalents (GEs) to N and S antigen concentration from clinical

samples, a panel of reagents with which to assess the performance of the RDTs representing
 multiple sources of target analyte protein, and the results from assessment of four different
 emergency use–authorized (EUA)/licensed (EUL) COVID-19 rapid antigen diagnostic tests.

## 67 MATERIALS AND METHODS

#### 68 Materials

69 Full-length recombinant N antigens expressed in *Escherichia coli* and in HEK293 mammalian

70 cells were purchased from Native Antigen (Kidlington, United Kingdom) and Acro Biosystems

71 (Newark, Delaware, USA), respectively. Recombinant S antigen, in a stabilized trimeric form

and expressed in HEK293 mammalian cells, was purchased from Acro Biosystems.

73 The following reagents were obtained through BEI Resources (Manassas, Virginia, USA); and

the US National Institute of Allergy and Infectious Diseases (NIAID)/US National Institutes of

75 Health (NIH), contributed by the US Centers for Disease Control and Prevention (CDC): SARS-

76 Related Coronavirus 2, Isolate USA-WA1/2020, Gamma-Irradiated (NR-52287), and Genomic

77 RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020 (NR-52285). The following

reagents were obtained through BEI Resources and NIAID/NIH: Human Coronavirus 229E (NR-

52726), and Human Coronavirus OC43 (NR-52725). NR-52287 used for N antigen

determination had assigned values for the concentration of infectious virus of  $2.8 \square \times \square 10^5 50\%$ 

- tissue culture infective dose (TCID<sub>50</sub>)/mL and RNA ( $4.1 \Box \times \Box 10^9$  copies/mL), determined prior
- to inactivation. The viral RNA control for RT-PCR was prepared from USA-WA1/2020 (47.5
- ng/mL total RNA with an estimated  $1.84 \times 10^7$  GEs/mL).

84	Using the GenBank sequence of the 419 as a full-length SARS-CoV-2 N protein, GenBank
85	accession number QHO62115.1, with an additional cleavage site and a polyhistidine tag, an
86	extinction coefficient was calculated based on ProtParam <sup>14</sup> of Abs 0.1% (= 1 g/L) of 0.959. This
87	extinction coefficient was used to confirm stock protein concentration of recombinant SARS-
88	CoV-2 antigen that was aliquoted and stored at -80°C.

The buffer diluent contained 1X phosphate-buffered saline (10 mM PBS, 2.7 mM potassium

90 chloride, 137 mM sodium chloride pH 7.4) with 1% bovine serum albumin (BSA), 1X PBS +

91 1% BSA. Negative swab pool diluent contains pooled discarded SARS-CoV-2 PCR-negative

92 human nasal swabs eluted into 1X PBS.

## 93 Clinical samples

94 De-identified nasal swab eluates were acquired from the Washington COVID-19 Biorepository

95 (Seattle, Washington, USA) or Boca Biolistics (Pompano Beach, Florida, USA). Nasal swab

96 eluates used in this study were prepared in either 1X PBS or Clinical Transport Medium (Noble

97 Biosciences, Gyeonggi-do, Republic of Korea).

## 98 Quantification of SARS-CoV-2 N and S antigens using SARS-CoV-2 antigen

### 99 immunoassays

An immunoassay detecting SARS-CoV-2 N and S antigens was developed using the Meso Scale
 Discovery (MSD) platform (Meso Scale Diagnostics, Rockville, Maryland, USA), which uses

102 electrochemiluminescence for detection.

103 Antibodies sourced from Sino Biological (Beijing, P.R. China) was used for N antigen detection

and an antibody pair from Leinco Technologies (Fenton, Missouri, USA) for S antigen detection.

105	The capture	antibodies	were labeled	with biotin	using the	e EZ-Link <sup>®</sup>	' Sulfo-NHS-LC-LC-
					0		

- 106 Biotinylation kit (ThermoFisher Scientific, Waltham, Massachusetts, USA) and the detector
- 107 antibodies were labeled with SULFO-TAG<sup>TM</sup> (GOLD SULFO-TAG NHS-Ester, Meso Scale
- 108 Diagnostics). Any unbound biotin or SULFO-TAG was removed using desalting columns
- 109 (Zeba<sup>TM</sup>, 40k MWCO, ThermoFisher Scientific). The concentrations of antibodies were
- 110 measured at 280 nm via a spectrophotometer (NanoDrop<sup>TM</sup> 2000C, ThermoFisher Scientific),
- and concentration of detector antibody following labeling was assigned 90% of the concentration
- 112 prior to desalting. Standards were prepared from recombinant HEK293-expressed full-length
- 113 SARS-CoV-2 N protein and stabilized trimeric S protein (Acro Biosystems).

#### 114 Clinical sample testing with SARS-CoV-2 antigen assays

115 N and S assays were run separately, using 25  $\mu$ L per well of the 0.5  $\mu$ g/mL biotinylated capture

antibody was used to coat a blocked SECTOR small spot streptavidin plate (Meso Scale

117 Diagnostics). Analysis of signal and quantification of unknowns relative to the standard curve

118 were conducted using Meso Scale Diagnostics' Discovery Workbench 4.0 software. For

119 quantification, standards and blank were fit with a 4-parameter log logit fit with 1/y2 weighting.

120 The lower limit of detection (LOD) was defined by the software's curve fitting. The lower limit

121 of quantification (LLOQ) was defined by the lowest concentration of standard with signal above

the following: the limit of blank plus 10 times the standard deviation of the limit of blank.<sup>15</sup> The

- upper limit of quantification (ULOQ) was defined by both software and a back-calculated
- 124 recovery average of 100%  $\pm$  20%. Standard curves spanned 0.128 pg/mL to 50 ng/mL of N

125 antigen,<sup>7</sup> and 0.128 pg/mL to 1,250 pg/mL of S antigen.

126	The concentration of SARS-CoV-2 N antigen was measured in 405 residual nasal swab eluates,
127	characterized by PCR at CLIA registered clinical laboratories, collected in July through
128	December 2020 in Washington state. Samples were selected across a range of Ct values from
129	original testing, with selection biased toward higher Ct values. Clinical samples either found or
130	anticipated to be over the detection range were diluted either 5-fold or 20-fold to bring them into
131	range, if volume allowed. Replicate well values for positives with a coefficient of variation
132	greater than 20% were repeated.

## 133 Molecular testing for SARS-CoV-2

134 Viral RNA was extracted from samples using the QIAamp<sup>®</sup> Viral RNA Mini Kit (Qiagen,

135 Valencia, California, USA) according to the manufacturer's instructions and eluted in 100 µL

136 buffer. A quantitative RT-PCR (qRT-PCR) assay to estimate the SARS-CoV-2 GE/mL was

developed using the N1 primer set developed by the CDC with primers and probe procured from

138 Integrated DNA Technologies (Coralville, Iowa, USA). Each 20 µL final reaction volume

139 contained 5 µL of 4X TaqPath<sup>™</sup> 1-Step RT-qPCR Master Mix (ThermoFisher Scientific), 0.5

140  $\mu$ L of probe (5  $\mu$ mol/L), 0.5  $\mu$ L each of forward and reverse primers (20  $\mu$ mol/L), 8.5  $\mu$ L of

141 nuclease-free water, and 5 µL of nucleic acid extract. Amplification was performed on an

142 Applied Biosystems<sup>™</sup> 7300 Real-Time PCR instrument (ThermoFisher Scientific).

143 Thermocycling conditions consisted of 15 minutes at 50°C, 2 minutes at 95°C, and 45 cycles of

144 3 seconds at 95°C and 30 seconds at 55°C. The cutoff for positive samples was less than 40

145 cycles. The median Cts were used to determine the viral GE concentration using a standard curve

146 from SARS  $\Box$  CoV-2 genomic RNA (Isolate USA  $\Box$  WA1/2020).

## 147 Benchmarking panel

148	Commercially sourced, full-length, His-tagged recombinant N protein as described above was
149	used. Radiation-inactivated, cultured SARS-CoV-2 virus (BEI Resources, NR-52287) stocks
150	were thawed and diluted into either buffer or negative swab pool. Serial dilutions were further
151	made into diluent and aliquots were frozen. Clinical nasal swab discards from five different
152	individuals, positive for SARS-CoV-2 by qRT-PCR, were selected and combined. The combined
153	samples were then serially diluted into negative swab pool, aliquoted, and frozen. The aliquots
154	were tested by qRT-PCR to quantify viral GE/mL. A benchmarking panel composed of dilutions
155	of recombinant proteins, inactivated viral lysate, and clinical specimen pool was then defined
156	and applied to all diagnostic tests in this study. The panel members were characterized for N
157	antigen concentration using the N antigen immunoassay as well as qRT-PCR for the clinical
158	specimen dilutions. The benchmarking panel is described in Table 1.

159 Table 1. Components of the benchmarking panel used in evaluation of rapid diagnostic

160	tests to detect nuc	leocapsid and	spike SARS-	CoV-2 antigens.
-----	---------------------	---------------	-------------	-----------------

Category	Antigen	Diluent/Matrix	Number of	N antigen
	source		dilutions	concentration range
Recombinant N	HEK293-	1X PBS, 1% BSA	10	0.1–50 ng/mL, 5,000
	expressed, His			ng/mL
	tagged			
Recombinant N	E. coli–	1X PBS, 1% BSA	10	0.1–50 ng/mL, 5,000
	expressed, His			ng/mL
	tagged			
Inactivated	Gamma-	1X PBS, 1% BSA	8	0.05–10 ng/mL,

virus	inactivated SARS-CoV-2 (202-WA-1)			representing 10 <sup>4</sup> –10 <sup>7</sup> GE/mL
Inactivated	Gamma-	Negative swab	8	0.05–10 ng/mL,
virus	inactivated SARS-CoV-2	pool		representing orders of $10^4$ – $10^7$ GE/mL
	(202-WA-1)			
Clinical	РАТН	Negative swab	16	0.025–225 ng/mL,
dilutions	biorepository	pool		representing orders of
				$10^{3}$ - $10^{7}$ GE/mL
Specificity	OC43 and	1X PBS, 1% BSA	1	Not detected; quantity
	229E cultured			of huCoV-specific N
	viral lysates			antigen not
				determined; 5,000
				TCID <sub>50</sub> /mL OC43 and
				10,000 TCID <sub>50</sub> /mL
				huCoV229E
Specificity	Diluent	Negative swab	1	Not detected
	controls	pool		
Specificity	Diluent	1X PBS, 1% BSA	1	Not detected
	controls			

161 Abbreviations: BEI, BEI Resources; BSA bovine serum albumin; *E. coli, Escherichia coli*; GE,

162 genome equivalent; PBS, phosphate-buffered saline; TCID<sub>50</sub>, 50% tissue culture infective dose.

#### 163 Rapid diagnostic tests used

- 164 Four EUA and/or EUL SARS-CoV-2 RDTs were evaluated using N antigen benchmarking
- panels: the Abbott BinaxNOW<sup>™</sup> COVID-19 Ag card test (EUA), Abbott Panbio<sup>™</sup> COVID-19
- 166 Ag Rapid Test Device (EUL), LumiraDx SARS-CoV-2 Ag Test (EUA), and SD Biosensor
- 167 STANDARD<sup>TM</sup> Q COVID-19 Ag Home Test (EUL). Tests were assigned, in no particular order,
- 168 identification numbers of RDT 1 through RDT 4, for the purpose of this publication, to de-
- 169 identify specific results.

#### 170 Evaluation of rapid diagnostic tests with benchmarking panels

- 171 Each RDT was run using a minimum of five replicates per panel concentration and type. Panel
- 172 member aliquots were thawed on ice and mixed gently. A pipetted volume of the panel mixed
- 173 into the rapid test-specific extraction buffer simulated the extracted swab material. Thereafter,
- the instructions for the rapid tests were followed and the diluted panel, at its final concentration
- in the extraction buffer, was added to the test according to instructions. All panel concentrations
- 176 were run until two levels of decreasing concentrations were negative for all replicates.

## 177 Statistical analysis of detection limits using benchmarking data

- 178 Two statistical models were developed to determine the relationships between (1) analyte
- 179 concentration and RDT test line intensity and (2) analyte concentration and probability of RDT
- 180 positivity. For (1), a sigmoid function was fit to the data of the form:

test line intensity =  $\frac{\alpha}{1 + \exp((m - \log_{10} conc)/s)}$ 

Where  $\alpha$ , m, s are parameters representing the shape of the sigmoid curve and *conc* is the analyte 181 182 concentration. This model was separately fitted to each data type (clinical dilution, inactivated 183 virus culture, and recombinant), and the step repeated for all four RDTs. For (2), a simple logistic regression model was fitted to the data, where analyte concentration was the independent 184 variable and the RDT result (1 = positive, 0 = negative) is the dependent variable. A categorical 185 186 factor representing the data type (clinical dilution, inactivated virus culture, recombinant protein) was included as a covariate to allow for data type–specific fitted curves. This step was repeated 187 188 for all four RDTs. The models described in (1) and (2) were fitted in a Bayesian framework using the R brms package.<sup>16</sup> Noninformative Gaussian priors were used for the parameters and 189 190 the models run for 5,000 iterations after a burn-in of 2,500 iterations. Convergence of chains was assessed using the R-hat statistic and visual checks. The final fitted lines and surrounding shaded 191 192 areas represent the median and 95% credible of the expected values of the posterior predictive 193 distributions.

## 194 Simulation of detection of clinical samples by rapid diagnostic tests

195 The detection limits derived from benchmarking data were used to simulate the detection of 196 clinical samples that had been characterized for SARS-CoV-2 N antigen concentration by MSD 197 assay. For each clinical sample, the quantity of N antigen was assumed to be concentrated into the source swab, which had been extracted and diluted into 3 mL transport medium. The quantity 198 199 of antigen was then divided by the manufacturer-designated volume of rapid test extraction 200 buffer to simulate the final concentration of N antigen that would be added to the test. Finally, 201 this final concentration was compared to detection limits generated in analysis of the 202 benchmarking data to determine whether the sample would be designated as detectable (Figure 203 1).

Figure 1. Representation of simulated clinical sample detection by rapid diagnostic test (RDT).

- A. Clinical samples consisting of swab eluate in 3 mL transport medium; N antigen
- 206 concentration measured. **B.** Total quantity of antigen assumed to be on swab. **C.** Total quantity
- of antigen is diluted in extraction buffer of RDT to calculate final concentration of N antigen
- added to RDT. D. Final concentration compared to 90% probability lower limit of detection from
- 209 benchmarking to determine whether detectable by RDT.



#### 210



## 212 **RESULTS**

#### 213 Analytical performance for the SARS-COV-2 N and S proteins

The SARS-CoV-2 N antigen immunoassay on the MSD platform had an average LOD of 0.45

- pg/mL (0.25 to 0.93 pg/mL range), an LLOQ of 3.2 pg/mL, and a ULOQ of 50 ng/mL. The
- SARS-CoV-2 S antigen immunoassay had an average LOD of 6.2 pg/mL (2.1 to 9.0 pg/mL
- range), an LLOQ of 80 pg/mL, and a ULOQ of 250 ng/mL. Both assays were nonreactive or
- below detection limits for panel diluents, transport media, and common human coronavirus
- lysates OC43 and 229E.

## 220 Distribution of N and S antigens in clinical samples

221 All 200 presumed positive samples and 100 of the 205 negative samples were analyzed by qRT-222 PCR for SARS-COV-2. Here, 182 samples were confirmed positive by qRT-PCR and 99 of the 223 negatives were confirmed negative, with one repeatedly testing positive by qRT-PCR. The 224 remaining negatives were assigned as qRT-PCR negative based on previously assigned qRT-225 PCR results, resulting in 183 PCR-positive samples and 222 PCR-negative samples. N and S 226 antigen quantification was conducted on all 405 specimens. A positive correlation was found 227 between the N antigen concentration and GEs (Figure 2A and 2B). The N antigen assays showed a high percent positive agreement (>95%) for specimens containing  $10^4$  or more GEs/mL 228 SARS-CoV-2 (Figure 3). The percent positive agreement progressively dropped with decreasing 229 concentrations of GEs. For the S antigen, the percent positive agreement was 86.4% at 10<sup>5</sup> 230 231 GEs/mL, with a sharp drop in agreement for lower concentrations. For all samples for which N antigen was within the LOQ of the assay (n = 120), the mean and median per GE N antigen 232 233 observed were 12.7 fg and 1.5 fg N antigen (range of 0.1 to 204.2 fg/GE). For concentrations of SARS-CoV-2 GEs less than 10<sup>4</sup> GEs/mL, the quantity of N antigen varied more widely for 234 positive samples within the LOQ, with a trend toward highest N antigen per GE. For all samples 235 236 for which S antigen was within the LOQ of the assay (n = 41), the mean and median per GE S antigen observed were 0.2 fg and 0.1 fg S antigen (range of 0.04 to 2.3 fg/GE). 237 Figure 2. A. Correlation between N antigen concentration (pg/mL) and N genome equivalents 238

(copies/mL). Mean cycle threshold (Ct) values are color coded to provide an indication of the
corresponding Ct values. **B.** Correlation between S antigen concentration (pg/mL) and N genome
equivalents (copies/mL). Mean Ct values are color coded to provide an indication of the
corresponding Ct values.





**Figure 3.** Antigen concentration over a range of SARS-CoV-2 genome equivalents detected by

- 246 Meso Scale Discovery antigen quantification. Characteristics of groups of viral genome
- equivalent concentrations are shown in the table below the graph. Bars indicate the median of the
- 248 group of antigen-positive points shown.



\*positive PCR, Ct < 40, but not quantified

#### 249

Abbreviations: Ct, cycle threshold; N, nucleocapsid; PCR, polymerase chain reaction; S, spike.

#### 251 Benchmarking panels

252 Benchmarking panels were prepared to span concentrations of N antigen corresponding to LODs

expected in rapid tests following dilution into the extraction buffer. As most RDTs only detect

- the N antigen, S antigen analysis was not included in the panel. HEK293-expressed and E. coli-
- expressed recombinant proteins were prepared in both buffer and negative swab pool dilution
- 256 matrices, and linear fit of measured concentration as compared to target concentration was
- greater than 0.98 over the range of the panels of 0.2 ng/mL to 50 ng/mL.

#### Quantification of inactivated virus and clinical dilutions, compared to genome equivalents 258

259	Though all panels were prepared from a single lot of inactivated SARS-CV-2 (BEI Resources),
260	comparisons between two lots showed that for each lot, the per-calculated GE concentration of N
261	antigen had a median of 1.0 fg/GE (range of 0.51 to 1.1 fg/GE) over the dilutions. In contrast,
262	when compared to $TCID_{50}$ , the median amount of N antigen per $TCID_{50}$ in the dilutions was
263	5,820 fg/TCID $_{50}$ for BEI Resources lot 70033322 and 668 fg/TCID $_{50}$ for lot 70035888. Both
264	irradiated virus and clinical pool samples behaved similarly, even in terms of the per GE
265	concentration of N antigen (Figure 4). For the clinical specimen pool dilution series, the median
266	per GE quantity of N antigen was 2.4 fg/GE (range of 1.2 to 5.3 fg/GE).
267	<b>Figure 4</b> The relation hair between N anticon concentration and concerns activalants for non-als
267	<b>Figure 4.</b> The relationnsip between N antigen concentration and genome equivalents for panels
268	of diluted clinical specimens and inactivated virus. Blue circles indicate the clinical pool dilution

series. Green squares and triangles indicate BEI Resources irradiated virus lot 7003588 in buffer 269

270 and negative swab pool, respectively.



272 Benchmarking of rapid antigen detection tests for SARS-CoV-2

Four RDTs were evaluated with the benchmarking panels: SD BIOSENSOR Abbott BinaxNOW
COVID-19 Ag card test, Abbott Panbio COVID-19 Ag Rapid Test Device, LumiraDx SARSCoV-2 Ag Test, and SD Biosensor STANDARD Q COVID-19 Ag Home Test. The tests were
anonymized using identification numbers RDT 1 through RDT 4, in no particular order, for
comparative presentations of the results.

278 **Reactivity of panel types** 

- 279 RDT line intensity scored either with a score card provided by the manufacturer or a preset
- universal score card allowed an assessment of the signal-dose response per panel member type.

281 An illustrative example is given in Figure 5 for RDT 1. Recombinant proteins from mammalian 282 and E. coli-based expression systems produced a strong dose-response signal on the RDTs and 283 were similarly reactive. Greater reactivity was observed with both inactivated viral culture and 284 diluted clinical positives, based on the final concentration of N antigen. Binary positive/negative 285 results were used to estimate the probability of detection at different antigen concentrations. This was performed for all four tests (Figure 6). All tests performed best against the clinical specimen 286 287 pool dilutions in terms of 90% probability of detection, and then differentially against the 288 different panel members. RDTs had lower reactivity to the inactivated virus when it was diluted into the buffer diluent versus negative swab pool diluent (Table 2). 289 Figure 5. Illustrative sub-benchmarking panel member analysis for SARS-CoV-2 rapid 290 291 diagnostic test 1. Circled positions indicate the replicates with a given test line intensity result for 292 the concentration of antigen (analyte) panel added. Each panel subset has been given a different color code: blue for clinical specimen pool, green for inactivated virus, and orange for 293 294 recombinant antigen. The size of the circles indicates the number of replicates supporting each 295 data point. Test line intensity is shown on a scale of 0 (negative) and 1 through 20, representing 296 from least to most intense visible test line of positive results.



#### 297



Figure 6. Probability of detection against antigen concentrations for the four antigen detection 299 rapid diagnostic tests per benchmarking panel type and diluent matrix. Probability of detection of 300 positive for the different benchmarking panel member types for each test in each panel (A, B, C, 301 and D). Blue lines indicate clinical specimen dilution; green lines represent inactivated virus; and 302 303 orange lines represent recombinant protein. Confidence intervals (95%) are indicated in 304 matched-color shading.



305



## 307 Table 2. Ninety percent probability of detection (95% confidence interval) of N antigen

# 308 final concentration for benchmarking panel categories.

	Concentration of N antigen (final concentration added to test) with 90% probability of detection, pg/mL				
Panel	Clinical	Inactivated	Inactivated	Recombinant	Specificity
category ►	positive	virus	virus	protein (E.	and diluent
				<i>coli</i> and	controls

	Diluted in	Diluted in	Diluted in	mammalian	
	negative swab	negative swab	buffer	expressed)	
	pool	pool			
RDT number				Diluted in	
•				buffer	
RDT 1	46.774	93.325	125.893	181.97	Not detected
	(33.113–	(75.858–	(102.329–	(154.882–	
	60.256)	114.815)	151.356)	208.93)	
RDT 2	23.988	54.954	58.884	74.131	Not detected
	(17.378–	(40.738–	(42.658–	(58.884-	
	31.623)	72.444)	79.433)	91.201)	
RDT 3	102.329	144.544	229.087	208.93	Not detected
	(70.795–	(104.713–	(165.959–	(165.959–	
	141.254)	194.984)	301.995)	263.027)	
RDT 4	21.38	22.909	42.658	128.825	Not detected
	(12.883–	(15.136–	(28.84–	(93.325–	
	32.359)	33.884)	63.096)	181.97)	

309 Abbreviations: *E. coli, Escherichia coli*; RDT, rapid diagnostic test.

# 310 Comparative benchmarking results

311 The clinical specimen pool dilution panels were plotted for all four tests, for comparison of

analytical performance of the RDTs (Figure 7). The modeled 90% probabilities of detection were

found to be 47, 24, 102, and 21 pg/mL of final concentration of N antigen added to test, for

RDTs 1 through 4 respectively (Table 2).

- **Figure 7.** Probability of test positivity versus final N antigen (analyte) concentration added to
- test for clinical positive dilutions. The four curves indicate the probability of test positivity for
- each rapid antigen test product. The shaded lines indicate 95% confidence intervals.



318



#### 320 Simulating clinical performance

One limitation of benchmarking is that the results are interpretable as a concentration inherently dependent upon assay configuration and the input volumes of the analyte. Interpretation of the final concentration of incoming analyte, as diluted into the assay extraction buffer, allowed normalization across RDTs but created the challenge of direct comparison to qRT-PCR values. If an identical swab were diluted into transport media (typically around 3 mL) and into RDT extraction buffer (typically around 300  $\mu$ L), the volume difference could create a 10-fold

327	disparity in analyte concentration from the swab. Figure 8 models this potential dilutional gain
328	when using RDTs to predict what may be observed in a paired swab sampling. Limits of
329	detection determined by the 90% cutoff were compared against the clinical sample set antigen
330	concentrations, with the assumption that extracted material present in the PCR would instead be
331	fully present in the extraction buffer for the rapid test, thus simulating a paired swab experiment.
332	The detection limits based on the concentration of N antigen added to the test were found to
333	affect the number of samples predicted to be detectable.
334	Figure 8. The predicted rapid diagnostic test (RDT) positivity from clinical samples based on
335	their antigen detection limit. Results are for RDT 3 (pink shading) and RDT 4 (blue shading),
336	shown as antigen concentration versus positivity (circle) or viral genome equivalent/mL versus
337	positivity (triangle).



338

339 Abbreviation: RDT , rapid diagnostic test.

RDTs 3 and 4, which had the highest and lowest analytical detection limits, respectively, based

on final concentration, were compared in this simulation. Overlap in N antigen–detectable and –

undetectable concentrations of GEs (Figure 8) was observed due to the spread of antigen

343 concentration per GE relationship, but the median GEs/mL between the detectable and

undetectable differed by about 2 orders of magnitude for all RDTs.

## 345 **DISCUSSION**

An open platform assay was developed and described to quantify the N and S antigens in SARS-

347 CoV-2–infected clinical specimens on the MSD platform. The assays showed good performance

348 against RT-PCR–confirmed cases and a panel of negative specimens. Quantification of both the

N and S antigens in specimens with associated viral load values showed a positive but not perfect correlation. As anticipated, a higher N antigen concentration was observed per GE in comparison to S antigen concentration, which has also been shown in plasma.<sup>17,18</sup> These results support the focus on N antigen for RDTs and overall correlation of antigen concentration with genome copy number<sup>9,19,20</sup>.

The antigen assay combined with the qRT-PCR was used to pedigree a panel of reagents

designed to benchmark N antigen RDTs. The benchmarking panel consisted of a dilution series

of recombinant N antigens, expressed in both prokaryotic and eukaryotic expression systems,

two sources of inactivated virus, and a clinical specimen pool. Four widely used tests, either

cleared by EUL or EUA, were evaluated against the panel: SD Biosensor STANDARD Q

359 COVID-19 Ag Home Test, Abbott COVID-19 Ag Rapid Test Device, Abbott BinaxNOW

360 COVID-19 Ag card test, and LumiraDx SARS-CoV-2 Ag test.

*E. coli*–expressed recombinant N antigen behaved similarly to N antigen expressed in
 mammalian cells on the N antigen assay. Inactivated virus contained N antigen concentration per
 viral GEs within the same range as observed in clinical samples. Comparison of the relationship
 between N antigen concentration and GEs versus TCID<sub>50</sub> across two lots from BEI Resources
 suggests that GEs are more reflective of the anticipated N antigen concentration.

The benchmarking results for the four tests highlight a range of reactivities against the different panel components. Consistently, all tests showed improved LOD to the clinical specimens over the other N antigen sources (inactivated virus and recombinant antigen). RDT 4 showed an improved response to negative swab diluent over buffer and highlights the need for comprehensive and test-specific data with a variety of materials before conclusions can be made.

Understanding the reactivity against inactivated virus and recombinant protein is valuable, as
these can be readily expressed, noninfectious sources of N antigen for emerging virus strains for
which there may be a concern for sequence-dependent false negativity.<sup>21-24</sup>

The 90% probability of detection, a proxy for LOD, for the clinical specimen pool ranged from 20 pg/mL to 100 pg/mL across the four tests. While the 90% probability of detection limit model is not a standardized method, it allows a continuous detection response function to be fit to standardized panels, rather than requiring custom dilutions for each test.<sup>25</sup> The simulated paired swab results generated by applying analytical detection limits to clinical samples was in alignment with observed clinical performance evaluations, indicating that RDTs detect a high

percentage of infections with viral loads associated with Ct values less than  $30^{26,27}$ 

381 While the analytical performance measured through benchmarking may be strongly indicative of 382 the clinical performance of the tests, it cannot be correlated directly to final performance. Some 383 of the factors that will influence the final performance are (1) relative efficiencies for absorption 384 and release of N antigen by the manufacturer's specific nasal swab and elution buffer; (2) the 385 dilution factor and original specimen equivalents loaded on to the test after all processing is 386 conducted; and (3) differing sensitivities of the test to the circulating SARS-CoV-2 strains in the 387 population being sampled. Although RDTs showed the best analytical performance against the 388 diluted clinical specimens pool, inclusion of recombinant protein sources can readily incorporate N antigens into the benchmarking panel with nonsynonymous mutations that may alter the 389 analytical performance of the diagnostic test.<sup>21,22,28</sup> 390

## 391 CONCLUSION

The benchmarking panel allowed rapid assessment of the analytical performance by
manufacturers and third parties in a manner that could be directly compared across RDTs for
SARS-CoV-2. Full characterization of both molecular and protein analytes allowed for
comparison of results across testing platforms. The benchmarking results were complementary to
efforts to produce international standards and to support clinical evaluations.

## 397 ACKNOWLEDGMENTS

398 The authors would like to acknowledge funding by the Bill & Melinda Gates Foundation 399 (https://www.gatesfoundation.org/) via grant INV-016821. The funder did not have any role in 400 the study design, data collection and analysis, decision to publish, or preparation of the 401 manuscript. Laboratories providing samples used in this work, accessed through the Washington 402 COVID-19 Biorepository, were The Everett Clinic (part of Optum), FidaLab, Northwest 403 Pathology, Bloodworks Northwest, the Washington State Public Health Laboratories, and the 404 University of Washington School of Medicine. Rapid diagnostic tests used in this work were 405 either purchased using grant funding from the Bill & Melinda Gates Foundation, or donated by 406 partners in support of research via grant from Abbott Laboratories and agreements from 407 LumiraDx and the Washington State Department of Health. Donors did not have any additional 408 role in the study design, data collection and analysis, decision to publish, or preparation of the 409 manuscript. Finally the authors would like to thank Brook Alemayehu and Terri Scott for 410 editorial support with the manuscript.

# 411 **REFERENCES**

412	1.	World Health Organization. Interim guidance: Antigen-detection in the diagnosis of SARS-
413		CoV-2 infection. https://www.who.int/publications-detail-redirect/antigen-detection-in-the-
414		diagnosis-of-sars-cov-2infection-using-rapid-immunoassays. Published Online: October 6,
415		2021.
416	2.	Pollock, N. R.; Berlin, D.; Smole, S. C.; Madoff, L. C.; Brown, C.; Henderson, K.; Larsen,
417		E.; Hay, J.; Gabriel, S.; Gawande, A. A.; Lennon, N. J. Implementation of SARS-CoV2
418		screening in K–12 schools using in-school pooled molecular testing and deconvolution by
419		rapid antigen test. J. Clin. Microbiol. 2021, 59, e01123-21.
420	3.	Revollo, B.; Blanco, I.; Soler, P.; Toro, J.; Izquierdo-Useros, J.; Puid, J.; Puid, X.; Navarro-
421		Pérez, V.; Casañ, C.; Ruiz, L.; Perez-Zsolt, D.; Videla, S.; Clotet, B.; Llibre, J. M. Same-
422		day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a
423		randomised controlled trial. Lancet Infect. Dis. 2021, 21, 1365-1372.
424	4.	Jimenez, A.; Rees-Channer, R. R.; Perera, R.; Perera, R.; Gamboa, D.; Chiodini, P. L.;
425		Gonzalez, I. J.; Mayor, A.; Ding, X. C. Analytical sensitivity of current best-in-class
426		malaria rapid diagnostic tests. Malar. J. 2017, 16.
427	5.	Brümmer, L. E.; Katzenschlager, S.; Gaeddert, M.; Erdmann, C.; Schmitz, S.; Bota, M.;
428		Grilli, M.; Larmann, J.; Weigand, M. A.; Pollock, N. R., Macé, A.; Carmona, S.; Ongarello,
429		S.; Sacks, J. A.; Denkinger, C. M. Accuracy of novel antigen rapid diagnostics for SARS-
430		CoV-2: a living systematic review and meta-analysis. PLOS Med. 2021, 18, e1003735.
431	6.	Dinnes, J.; Deeks, J. J.; Berhane, S.; Dittrich, S.; Emperador, D.; Takwoingi, Y.;
432		Cunningham, J.; Beese, S.; Dretzke, J.; di Ruffano, L. F.; Harris, I. M.; Price, M. J.; Taylor-
433		Phillips, S.; Hooft, L.; Mg Leeflang, M.; Spijker, R.; Van den Bruel, A.; Cochrane COVID-

434		19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests
435		for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 2021, 3, Cd013705.
436		DOI: 10.1002/14651858.CD013705.pub2.
437	7.	Corman, V. M.; Haage, V. C.; Bleicker, T.; Schmidt, M. L.; Mühlemann, B.; Zuchowski,
438		M.; Jo, W. K.; Tscheak, P.; Möncke-Buchner, E.; Müller, M. A.; Krumbholz, A.; Drexler,
439		J. F.; Drosten, C. Comparison of seven commercial SARS-CoV-2 rapid point-of-care
440		antigen tests: a single-centre laboratory evaluation study. Lancet Microbe. 2021, 2, e311-
441		e319.
442	8.	Schroeder, L. F.; Bachman, M. A.; Idoni, A.; Gegenheimer-Holmes, J.; Kronick, S. L.;
443		Valdez, R.; Lephart, P. R. Predicting direct-specimen SARS-CoV-2 assay performance
444		using residual patient samples. J. Appl. Lab. Med. 2021, 7, 661-673.
445	9.	Denzler, A.; Jacobs, M. L.; Witte, V.; Schnitzler, P.; Denkinger, C. M.; Knop, M. Rapid
446		comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests. Infection. [Online
447		early access]. https://doi.org/10.1101/2021.07.29.21261314. Published Online: April 9,
448		2022.
449	10.	Bekliz, M.; Adea, K.; Essaidi-Laziosi, M.; Sacks, J. A.; Escadafa, C.; Kaiser, L.; Ecker, I.
450		SARS-CoV-2 antigen-detecting rapid tests for the delta variant. Lancet Microbe. 2022, 3,
451		e90.
452	11.	Kontogianni, K.; Cubas-Atienzar, A. I.; Wooding, D.; Buist, K.; Thompson, C. R.;
453		Williams, C. T.; Baldwin, L.; Escadafal, C.; Sacks, J. A.; Adams, E. R.; Edwards, T. Lateral
454		flow antigen tests can sensitively detect live cultured virus of the SARS-CoV-2 B1.1.7
455		lineage. J. Infect. 2021, 83, e1-e4.

456	12.	Bekliz, M.; Adea, K.; Essaidi-Laziosi, M; Sacks, J. A.; Escadafal, C.; Kaiser, L.; Eckerle,	I.
-----	-----	---	----

- 457 SARS-CoV-2 rapid diagnostic tests for emerging variants. *Lancet Microbe*. **2021**, *2*, e351.
- 458 13. Stanley, S.; Hamel, D. J.; Wolf, I. D.; Riedel, S.; Dutta, S.; Contreras, E.; Callahan, C. J.;
- 459 Cheng, A.; Arnaout, R.; Kirby, J. E.; Kanki, P. J. Limit of detection for rapid antigen testing
- 460 of the SARS-CoV-2 Omicron and Delta variants of concern using live-virus culture. J. Clin.
- 461 *Microbiol*. [Online early access]. <u>https://doi.org/10.1128/jcm.00140-22</u>. Published Online:
- 462 April 20, 2022.
- 14. ExPASy ProtParam tool. https://web.expasy.org/protparam/. Accessed May 19, 2021.
- 15. Armbruster, D. A.; Pry, T. Limit of blank, limit of detection and limit of quantitation. *Clin*.
- 465 *Biochem. Rev.* **2008**, *29*, S49-S52.
- 466 16. Bürkner, P. C. brms: an R package for Bayesian multilevel models using stan. *J. Stat.*467 *Softw.* 2017, 80, 1-28.
- 17. Sigal, G. B.; Novak, T.; Mathew, A. Measurement of SARS-CoV-2 antigens in plasma of
- 469 pediatric patients with acute COVID-19 or MIS-C using an ultrasensitive and quantitative
- 470 immunoassay. *MedRxiv Prepr. Serv. Health Sci.* [Online early access]. DOI:
- 471 10.1101/2021.12.08.21267502. Published Online: December 9, 2021.
- 472 18. Hingrat, Q. L.; Visseaux, B.; Laouenan, C.; Tubiana, S.; Bouadma, L.; Yazdanpanah, Y.;
- 473 Duval, X.; Burdet, C.; Ichou, H.; Damond, F.; Bertine, M.; Benmalek, N.; Choquet, C.;
- 474 Timsit, J-F.; Ghosn, J.; Charpentier, C.; Descamps, D.; Houhou-Fidouh, N. Detection of
- 475 SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker
- and new testing alternatives. *Clin. Microbiol. Infect.* **2021**, *27*, 789.e1-789.e5.
- 477 19. Pollock, N. R.; Savage, T. J.; Wardell, H; Lee, R. A.; Mathew, A.; Stengelin, M.; Sigal, G.
- 478 B. Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in

- 479 nasopharyngeal samples from children and adults using an ultrasensitive and quantitative
  480 antigen assay. J. Clin. Microbiol. 2021, 59.
- 481 20. Wang, H.; Hogan, C. A.; Verghese, M.; Solis, D.; Sibai, M.; Huang, C.; Zehnder, J.; Sahoo,
- 482 M. K.; Pinsky, B. A. Ultra-sensitive severe acute respiratory syndrome coronavirus 2
- 483 (SARS-CoV-2) antigen detection for the diagnosis of coronavirus disease 2019 (COVID-
- 484 19) in upper respiratory samples. *Clin. Infect. Dis.* **2021**, *73*, 2326-2328.
- 485 21. Bourassa, L.; Perchetti, G. A.; Phung, Q.; Lin, M. J.; Mills, M. G.; Roychoudhury, P.;
- 486 Harmon, K. G.; Reed, J. C.; Greninger, A. L. A SARS-CoV-2 nucleocapsid variant that
- 487 affects antigen test performance. J. Clin. Virol. 2021, 41, 104900.
- 488 22. Jian, M-J.; Chung, H-Y.; Chang, C-K.; Lin, J-C.; Yeh, K-M.; Chen, C-W.; Lin, D-Y.;
- 489 Chang, F-Y.; Hung, K-S.; Perng, C-L.; Shang, H-S. SARS-CoV-2 variants with T135I
- 490 nucleocapsid mutations may affect antigen test performance. *Int. J. Infect. Dis.* **2022**, *114*,
- 491 112-114.
- 492 23. Barrera-Avalos, C.; Luraschi, R.; Vallejos-Vidal, E.; Mella-Torres, A.; Hernández, F.;
- 493 Figueroa, M.; Rioseco, C.; Valdés, D.; Imarai, M.; Acuña-Castillo, C.; Reyes-López, F. E.;
- 494 Sandino, A. M. The rapid antigen detection test for SARS-CoV-2 underestimates the
- 495 identification of COVID-19 positive cases and compromises the diagnosis of the SARS-
- 496 CoV-2 (K417N/T, E484K, and N501Y) variants. *Front. Public Health.* **2022**, *9*, 780801.
- 497 24. Bayart, J. L.; Degosserie, J.; Favresse, J.; Gillot, C.; Didembourg, M.; Phanio Djokoto, H.;
- 498 Verbelen, V.; Roussel, G.; Maschietto, C.; Mullier, F.; Dogné, J-M.; Douxfils, J. Analytical
- 499 sensitivity of six SARS-CoV-2 rapid antigen tests for Omicron versus Delta variant.
- 500 *Viruses.* **2022**, *14*, 654.

501	25.	Clinical and Laboratory Standards Institute (CLSI). EP12-A2: User Protocol for Evaluation
502		of Qualitative Test Performance; Approved Guideline, 2nd ed.; CLSI: Wayne,
503		Pennsylvania, USA, 2008.
504	26.	McKay, S. L.; Tobolowsky, F. A.; Moritz, E. D.; Hatfield, K. M.; Bhatnagar, A.; LaVoie S.
505		P.; Jackson, D. A.; Lecy, K. D.; Bryant-Genevier, J.; Campbell, D.; Freeman, B.; Gilbert, S.
506		E. Folster; J. M.; Medrzycki, M.; Shewmaker, P. L.; Bankamp, B.; Radford, K. W.;
507		Anderson, R.; Bowen, M. D.; Negley, J.; Reddy, S. C.; Jernigan, J. A.; Brown, A. C.;
508		McDonald, L. C.; Kutty, P. K.; CDC Infection Prevention and Control Team and the CDC
509		COVID-19 Surge Laboratory Group. Performance evaluation of serial SARS-CoV-2 rapid
510		antigen testing during a nursing home outbreak. Ann. Intern. Med. 2021, 174, 945-951.
511	27.	Begum, M. N.; Jubair, M.; Nahar, K; Rahman, S.; Talha, M.; Sarker, M. S.; Nasir Uddin,
512		A. K. M.; Khaled, S.; Uddin, M. S.; Li, Z.; Ke, T.; Rahman, M. Z.; Rahman, M. Factors
513		influencing the performance of rapid SARS-CoV-2 antigen tests under field condition. J.
514		<i>Clin. Lab. Anal.</i> <b>2022</b> , <i>36</i> , e24203.
515	28.	Jungnick, S.; Hobmaier, B.; Mautner, L.; Hoyos, M.; Haase, M.; Baiker, A.; Lahne, H.;
516		Eberle, U.; Wimmer, C.; Hepner, S.; Sprenger, A.; Berger, C.; Dangel, A.; Ippisch, S.;
517		Hahner, S.; Wildner, M.; Liebl, B.; Ackermann, N.; Sing, A.; Fingerle, V. In vitro rapid
518		antigen test performance with the SARS-CoV-2 variants of concern B.1.1.7 (Alpha),
519		B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta). Microorganisms. 2021, 9, 1967.